Research programme: norepinephrine reuptake inhibitors - Pfizer
Alternative Names: NRI-022; NRI-193; WAY-253203; WAY-256805; WAY-260022; WAY-315193; WAY-318068Latest Information Update: 04 Nov 2017
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Indoles
- Mechanism of Action Adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Attention-deficit hyperactivity disorder; Major depressive disorder; Pain; Vasomotor symptoms
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in USA (PO)